Key takeaways
- Biomarkers like fasting insulin, lipid subfractions, and hormone levels can shift dramatically in weeks, not years.
- A 120-day review cadence aligns with red blood cell turnover (HbA1c window) and cellular tissue adaptation.
- 120-day re-evaluations prevent protocols from remaining static after your biology has already adapted.
- One dedicated provider tracks your trajectory across every visit, ensuring true continuity of care.
The 364-Day Blind Spot in Conventional Healthcare
In traditional medicine, you visit a clinic, undergo basic bloodwork, and receive a letter weeks later saying your results were normal. You are not seen again for an entire year.
During those twelve months, insulin sensitivity can degrade, cardiovascular particle counts can climb, and hormone levels can shift. By the time an annual test flags a problem, months of sub-optimal health and subclinical damage have already occurred.
Aligning With Human Physiology
One hundred twenty days is a physiological sweet spot. It reflects the lifespan of a red blood cell (making it the ideal window to evaluate HbA1c and glycemic control), gives lifestyle and therapeutic protocols adequate time to produce measurable change, and provides enough frequency to course-correct before bad trends take hold.
Every 120 days at Averra Life, your updated diagnostics flow into RAVE Mobile. Your dedicated provider reviews the trajectory with you and updates your Personal Health Plan for the upcoming cycle.
Frequently asked questions
Does every 120-day checkup require a full blood draw?
Your dedicated provider selects focused diagnostic panels based on your active protocols and baseline findings, alternating comprehensive annual baselines with targeted 120-day progress markers.